Vinblastine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vinblastine: From Hodgkin’s Lymphoma to Rhabdomyosarcoma
One-Sentence Summary
Vinblastine is a vinca alkaloid antineoplastic agent classically used in combination regimens for Hodgkin’s lymphoma, testicular cancer, and Kaposi’s sarcoma. The TxGNN model predicts it may be effective for Rhabdomyosarcoma (RMS), with 0 registered clinical trials but 15 publications — including direct case-level vinblastine use in RMS, Phase II data from the structurally analogous vinorelbine, and preclinical mechanistic studies — currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hodgkin’s lymphoma, testicular cancer, Kaposi’s sarcoma (classical pharmacological use; no Philippines registration) |
| Predicted New Indication | Rhabdomyosarcoma |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L3 |
| Philippines Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacological knowledge, Vinblastine is a naturally derived vinca alkaloid that binds to tubulin dimers, inhibiting microtubule polymerization and blocking mitotic spindle assembly. This arrests rapidly dividing cells in metaphase and ultimately triggers apoptosis. As a drug class, vinca alkaloids have been foundational in pediatric oncology for decades.
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, characterized by a high mitotic index — an inherent vulnerability to microtubule-disrupting agents. Preclinical studies confirm that both vincristine and vinblastine demonstrate differential but meaningful activity against RMS xenograft models, with sensitivity linked to intracellular vinca alkaloid retention and GTP-tubulin dynamics (PMID 3329524, PMID 6692363). At the clinical level, vinblastine has been directly incorporated into combination regimens for refractory prostatic RMS in pediatric case reports (PMID 2451411), and a 2023 case report documented partial response to a cisplatin + vinblastine-containing salvage regimen in perianal RMS (PMID 38050209).
The broader evidence base draws on a well-established class-effect argument: vinorelbine, a semi-synthetic vinca alkaloid with the same tubulin-binding mechanism, has accumulated Phase II clinical data specifically in pediatric RMS (PMID 22633624, PMID 15378498, PMID 12115359), forming the backbone of the European RMS maintenance protocol. Additionally, synthetic lethality between PLK1 inhibitors and microtubule-destabilizing drugs — including vinblastine — has been confirmed in preclinical RMS models (PMID 26024389), pointing toward rational combination strategies for future trials.
Clinical Trial Evidence
Currently no related clinical trials registered for Vinblastine specifically in Rhabdomyosarcoma.
Note: Phase II clinical trial evidence for the vinca alkaloid analogue vinorelbine in pediatric RMS exists within the SFCE program (see Literature Evidence below). A completed Phase 1/2 trial of INT230-6 — an intratumoral formulation containing vinblastine and cisplatin — enrolled 111 patients with advanced refractory solid tumors (NCT03058289), providing indirect safety confirmation for vinblastine in an oncology setting.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22633624 | 2012 | Phase II (vinorelbine analogue) | European Journal of Cancer | Vinorelbine + low-dose cyclophosphamide in relapsed/refractory pediatric solid tumors; demonstrated efficacy specifically in the RMS subgroup, with acceptable tolerability |
| 15378498 | 2004 | Pilot Clinical Study (vinorelbine) | Cancer | Vinorelbine + low-dose cyclophosphamide for refractory/recurrent sarcoma; established optimal dosing and served as foundation for the upcoming European RMS maintenance protocol |
| 12115359 | 2002 | Clinical Study (vinorelbine) | Cancer | Vinorelbine in previously treated pediatric sarcomas; evidence of activity specifically in rhabdomyosarcoma, supporting vinca alkaloid class-effect |
| 41216926 | 2026 | Retrospective Cohort | Pediatric Blood & Cancer | CWS-96 and CWS-2002P prospective trials for soft tissue sarcoma; risk stratification and evaluation of different chemotherapy regimens in high-risk patients |
| 22156656 | 2011 | Pilot Study | Oncotarget | Metronomic 4-drug regimen (including vinca alkaloid) for resistant pediatric cancers; supports low-dose continuous vinca alkaloid strategies in refractory settings |
| 26024389 | 2015 | Preclinical Mechanistic | Cell Death and Differentiation | PLK1 inhibitors synergistically induce apoptosis with microtubule-destabilizing drugs (including vinblastine) in preclinical RMS models; synthetic lethality confirmed, with mechanistic elucidation |
| 3329524 | 1987 | Mechanistic Study | Anti-Cancer Drug Design | Tubulin as therapeutic target in RMS; role of GTP in differential sensitivity of human RMS xenografts to vincristine vs. vinblastine; only vincristine and vinblastine demonstrate clinical utility |
| 6692363 | 1984 | Preclinical Study | Cancer Research | Intrinsic sensitivity determinants of vinca alkaloids in three pediatric RMS xenograft lines; vinblastine demonstrated substantial activity in sensitive lines (Rh28), supporting line-specific responsiveness |
| 38050209 | 2023 | Case Report / Literature Review | Medicine | Perianal/perineal RMS in adult: partial response achieved with nivolumab + dacarbazine + cisplatin + vinblastine after failure of prior epirubicin/ifosfamide/bevacizumab; surgical resection subsequently performed |
| 2451411 | 1987 | Case Report | Acta Urologica Japonica | Refractory prostatic RMS in a 3-year-old: rapid and marked reduction of bulky pelvic mass with PVP therapy (cisplatin + vinblastine + peplomycin) after failure of first-line VACA regimen |
Philippines Market Information
Vinblastine is currently not registered in the Philippines (FDA Philippines). There are no active marketing authorizations, approved products, or dosage forms on record. Procurement for clinical use would require special importation or compassionate use authorization.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Vinca alkaloid — natural product class) |
| Myelosuppression Risk | High — leukopenia and neutropenia are the primary dose-limiting toxicities; thrombocytopenia also observed |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | CBC with differential (at nadir, typically Day 7–10 post-dose), liver function tests (vinblastine is hepatically metabolized), renal function, neurological examination for peripheral neuropathy |
| Handling Protection | Must follow cytotoxic drug handling regulations; classified as a vesicant — extravasation causes severe tissue necrosis requiring immediate intervention; intrathecal administration is absolutely contraindicated and potentially fatal |
Safety Considerations
Please refer to the package insert for safety information.
Formal safety data (key warnings, contraindications, drug-drug interactions) was not available in the current Evidence Pack (Data Gap DG001). Full package insert review from a registered jurisdiction (e.g., FDA USA, EMA) is required before any clinical use or protocol development.
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: The available literature supports a mechanistically plausible and historically grounded rationale for vinblastine in rhabdomyosarcoma, with direct case-level clinical use confirmed and strong class-effect evidence from the Phase II vinorelbine program. However, evidence is at L3 (no dedicated controlled trial for vinblastine in RMS), the drug is completely unregistered in the Philippines with no local safety data, and a critical safety data gap (DG001) prevents entry into formal safety evaluation.
To proceed, the following is needed:
- Retrieve full prescribing information (package insert) from a reference jurisdiction to document warnings, contraindications, and drug interactions — blocking gap for safety evaluation
- Confirm mechanism of action via DrugBank API query (DG002)
- Conduct a systematic review of vinca alkaloid class-effect evidence in RMS to define the regulatory and scientific justification
- Identify the regulatory pathway in the Philippines for importing or using an unregistered cytotoxic agent (compassionate use, special access scheme)
- Consider a formal Phase II investigator-initiated trial design using vinblastine within a metronomic or PLK1-combination framework, building on the existing vinorelbine precedent in European RMS protocols
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.